close
close

Vivos Therapeutics Receives Breakthrough FDA 510(k) Clearance for the Treatment of Moderate to Severe Sleep Apnea and Snoring in Children Page 1

Posted on by Vaseline
Vivos Therapeutics Receives Breakthrough FDA 510(k) Clearance for the Treatment of Moderate to Severe Sleep Apnea and Snoring in Children Page 1

Vivos is poised to disrupt the critically important pediatric obstructive sleep apnea (OSA) market with new FDA clearance and a new strategic marketing and distribution model

Vivos DNA device now approved to reduce and treat snoring moderate to severe OSA in children aged 6 to 17 years

Related Posts